nfx-179
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jul 31, 2020 (NCT04435665)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
MAP3K1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05195762 | Phase 2 | Jun 30, 2023 | NFlection Therapeutics, Stanford University |
| NCT05005845 | Phase 2 | Sep 20, 2021 | NFlection Therapeutics |
| NCT04435665 | Phase 2 | Jul 31, 2020 | NFlection Therapeutics |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| NFlection Therapeutics | For profit | 3 | 2 | 1 | 2020 |
| Stanford University | Academic/Hospital | 1 | 1 | 1 | 2023 |
2 organizations
Page 1 / 1